TY - JOUR T1 - Comparison of Gadoterate Meglumine and Gadobutrol in the MRI Diagnosis of Primary Brain Tumors: A Double-Blind Randomized Controlled Intraindividual Crossover Study (the REMIND Study) JF - American Journal of Neuroradiology JO - Am. J. Neuroradiol. SP - 1681 LP - 1688 DO - 10.3174/ajnr.A5316 VL - 38 IS - 9 AU - K.R. Maravilla AU - D. San-Juan AU - S.J. Kim AU - G. Elizondo-Riojas AU - J.R. Fink AU - W. Escobar AU - A. Bag AU - D.R. Roberts AU - J. Hao AU - C. Pitrou AU - A.J. Tsiouris AU - E. Herskovits AU - J.B. Fiebach Y1 - 2017/09/01 UR - http://www.ajnr.org/content/38/9/1681.abstract N2 - BACKGROUND AND PURPOSE: Effective management of patients with brain tumors depends on accurate detection and characterization of lesions. This study aimed to demonstrate the noninferiority of gadoterate meglumine versus gadobutrol for overall visualization and characterization of primary brain tumors.MATERIALS AND METHODS: This multicenter, double-blind, randomized, controlled intraindividual, crossover, noninferiority study included 279 patients. Both contrast agents (dose = 0.1 mmol/kg of body weight) were assessed with 2 identical MRIs at a time interval of 2–14 days. The primary end point was overall lesion visualization and characterization, scored independently by 3 off-site readers on a 4-point scale, ranging from “poor” to “excellent.” Secondary end points were qualitative assessments (lesion border delineation, internal morphology, degree of contrast enhancement, diagnostic confidence), quantitative measurements (signal intensity), and safety (adverse events). All qualitative assessments were also performed on-site.RESULTS: For all 3 readers, images of most patients (>90%) were scored good or excellent for overall lesion visualization and characterization with either contrast agent; and the noninferiority of gadoterate meglumine versus gadobutrol was statistically demonstrated. No significant differences were observed between the 2 contrast agents regarding qualitative end points despite quantitative mean lesion percentage enhancement being higher with gadobutrol (P < .001). Diagnostic confidence was high/excellent for all readers in >81% of the patients with both contrast agents. Similar percentages of patients with adverse events related to the contrast agents were observed with gadoterate meglumine (7.8%) and gadobutrol (7.3%), mainly injection site pain.CONCLUSIONS: The noninferiority of gadoterate meglumine versus gadobutrol for overall visualization and characterization of primary brain tumors was demonstrated.AEadverse eventCNRcontrast-to-noise ratioGBCAgadolinium-based contrast agentLSleast-squaresr1relaxivity ER -